Global Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type (Chemotherapy, Hormonal Therapy, Immunotherapy & Radiotherapy), By Drug Delivery Method (Oral Route, Intravenous, Subcutaneous) and by Region (North America, Europe, Asia-Pacific, South America, Middle East, and Africa) Analysis and Forecast 2022-2030

Key Market Insights

The global castration-resistant prostate cancer (CRPC) therapeutics market was valued at USD 9.24 Billion in 2021 and is projected to reach USD 15.62 Billion by 2030, at a CAGR of 7.8%. Castration-resistant prostate cancer (CRPC) is characterized by repeated increases in serum prostate-specific antigen (PSA) levels or/and advancement of metastatic spread in the presence of castrate testosterone levels. This usually happens when the cancer has reached a stage where it no longer fully responds to testosterone-lowering therapies. The rising clinical studies being conducted to treat metastatic castration-resistant prostate cancer due to the high rate of prostate cancer, which develops into castrate-resistant prostate cancer a few years after diagnosis, the incidence of castrate-resistant prostate cancer is increasing worldwide.

The key elements that are expected to propel market expansion include an unhealthy lifestyle, expanding use of innovative medications, and an increase in the occurrence of castrate-resistant prostate cancer. The market's growth rate is also being fueled by key players' efforts in R&D and the need for quicker treatment choices.

COVID-19 ANALYSIS

The COVID-19 outbreak is anticipated to have a negative impact on growth of the global Castration-resistant prostate cancer (CRPC) market. The majority of hospitals and cancer center have decreased their capacity for outpatient care and implemented triage. This caused numerous unnecessary surgical treatments to be postponed globally. Although it has been curbed by now as the rising cases COVID-19 has fallen due to resuming the healthcare operations.

Rising Rate of Prostate Cancer Propelling Market Growth

The rising incidences of prostate cancer is now common globally aiding the market growth of the global castration-resistant prostate cancer therapeutics market. For instance, according to American Cancer Society, over the past ten years, the percentage of prostate cancer cases identified at an advanced stage rose from 3.9% to 8.2%. Moreover, around 268,490 new cases have been registered of prostate cancer in US for 2022. The rising trend of early diagnosis of the illness is linked to a positive prognosis.

Rising Geriatric Population Worldwide to Propel Market Growth

The rising geriatric population is aiding the market growth as it is common in older age. The prostate cancer is the second most common cancer in men globally. For instance, according to WCRF International, there were more than 1.4 million new cases of prostate cancer in 2020.

Lack of Standardized Treatment Hampering Market Growth

The factors affecting the growth of the market is the lack of a consistent treatment sequence. It is likely to hamper the growth on the global castration-resistant prostate cancer therapeutics market. There are many different treatment options available depending upon the patient's nature and the doctor's preference. The market for castrate-resistant prostate cancer is expected to rise as a result of these causes.

Based on the type, the market is categorized into chemotherapy, hormonal therapy, immunotherapy & radiotherapy. On the basis of drug delivery method, the market is categorized into oral route, intravenous & subcutaneous. Based on the region, the market is categorized into North America, Europe, Asia-Pacific, South America, Middle East and Africa.

Type Insights

On the basis of type, the market is categorized into chemotherapy, hormonal therapy, immunotherapy & radiotherapy. The hormonal therapy is expected to dominate the market share of global castration-resistant prostate cancer (CRPC) therapeutics market owing to availability of a large number of approved medications, the introduction of new medications, and the expansion of product indication. The market for castrate-resistant prostate cancer is anticipated to rise as innovative medicines are increasingly being developed to meet unmet needs and existing treatment choices.

The global castration-resistant prostate cancer (CRPC) therapeutics market is categorized into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. Europe is expected to dominate the market share of global castration-resistant prostate cancer (CRPC) therapeutics market owing to high frequency of the disease, the existence of regional players, and the advantageous reimbursement regulations are responsible for this expansion. Another factor increasing the prevalence of diseases is changing lifestyle, a collaboration between several governments and private institutions, including the European Organization for Research and Treatment of Cancer (EORTC) and the European Medicines Agency (EMA), to create special programs concentrating on various approaches to drug development.

However, Asia Pacific is anticipated to emerge as the fastest-growing region over the forecast period. The market is driven by the existence of prominent oncology firms and a surge in R&D spending in nations like China and Japan. Prostate cancer medications are now being developed more frequently as a result of this. Additionally, clinical trials in developing nations are less expensive than those in developed nations boosting market development.

List of Companies Profiled:

• Amgen Inc.
• Arcus Biosciences
• Arvinas
• Astellas Pharma Inc.
• AstraZeneca
• Bayer AG
• Blue Earth Therapeutics
• Dendreon Intravenouss LLC
• ESSA PHARMA
• Exelixis, Inc.
• Forma therapeutics
• Hinova
• Janux Therapeutics
• Johnson & Johnson Services, Inc.
• Novartis AG
• Oncternal Therapeutics, Inc.
• Pfizer Inc.
• Sanofi
• Others

Key Industry Developments:

June 2022- Blue Earth Therapeutics announced positive results from a series of preclinical analysis designed to evaluate the bio distribution and potential therapeutic efficacy in the treatment of prostate cancer preclinical models.

March 2022- Novartis announced that the US Food and Drug Administration (FDA) approved PluvictoTM for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

February 2022- Arvinas completed Phase 1 and interim Phase 2 ARDENT data for bavdegalutamide to demonstrate clinical benefit in men with metastatic castration-resistant prostate cancer.

January 2022- Pfizer has collaborated with Dren Bio to discover and advance multiple therapeutic antibodies using its targeted myeloid engager and phagocytosis platform for the treatment of cancer.

February 2020- Exelixis announced encouraging results for cabozantinib in combination with atezolizumab in metastatic castration-resistant prostate cancer.

Segmentation:

By Type

• Chemotherapy
• Hormonal Therapy
• Immunotherapy
• Radiotherapy

By Drug Delivery Method

• Oral Route
• Intravenous
• Subcutaneous

By Region

• North America- U.S., Mexico, Canada
• Europe- UK, France, Germany, Italy, Spain, Rest of Europe
• Asia-Pacific- China, Japan, India, South Korea, Rest of Asia Pacific
• South America- Brazil, Argentina, Colombia, Rest of South America
• The Middle East and Africa- GCC, South Africa, Rest of Middle East & Africa